{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:44:29Z","timestamp":1789685069646,"version":"4.0.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jtho.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T13:17:45Z","timestamp":1535462265000},"page":"1269-1283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Scientific Advances and New Frontiers in Mesothelioma Therapeutics"],"prefix":"10.1016","volume":"13","author":[{"given":"Luciano","family":"Mutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.S.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavitt A.","family":"Woodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Jablons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.06.011_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant pleural mesothelioma: a comprehensive review","volume":"13","author":"Ismail-Khan","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.jtho.2018.06.011_bib2","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clgc.2015.05.009","article-title":"Malignant mesothelioma of the tunica vaginalis: a rare\u00a0neoplasm\u2013case report and literature review","volume":"13","author":"Segura-Gonzalez","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5858\/arpa.2011-0039-RA","article-title":"Mesothelioma not associated with asbestos exposure","volume":"136","author":"Jasani","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"Roe","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtho.2018.06.011_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J","article-title":"Simian virus 40 and human tumors: it is time to study mechanisms","volume":"76","author":"Carbone","year":"1999","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jtho.2018.06.011_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant\u00a0mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib7","first-page":"875","article-title":"Simian virus 40: the link with human malignant mesothelioma is well established","volume":"20","author":"Carbone","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib10","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1073\/pnas.1105887108","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.06.011_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja11.10125","article-title":"Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation","volume":"195","author":"Olsen","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.jtho.2018.06.011_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncponc1039","article-title":"Advances in the systemic therapy of malignant pleural mesothelioma","volume":"5","author":"Fennell","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.06.011_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers - from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.06.011_bib16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted\u00a0therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib17","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for malignant pleural mesothelioma: an international guidelines review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2018.06.011_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2018.06.011_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","article-title":"Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model","volume":"1203","author":"Hillegass","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jtho.2018.06.011_bib20","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1073\/pnas.0808816106","article-title":"Activated TNF-alpha\/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice","volume":"106","author":"Altomare","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.06.011_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.06.011_bib24","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations\u00a0induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2018.06.011_bib25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<740::AID-IJC12>3.0.CO;2-5","article-title":"Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes","volume":"78","author":"Mutti","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib26","first-page":"161","article-title":"Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone","volume":"11","author":"Valle","year":"2003","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib27","doi-asserted-by":"crossref","first-page":"9155","DOI":"10.1038\/sj.onc.1208180","article-title":"Malignant mesothelioma as both\u00a0a challenge and an opportunity","volume":"23","author":"Mutti","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2018.06.011_bib28","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1517\/14712598.2015.1116515","article-title":"Tremelimumab for the treatment of malignant mesothelioma","volume":"15","author":"Guazzelli","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jtho.2018.06.011_bib29","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib30","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study","volume":"83","author":"Asoul","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib31","series-title":"Genomic and Personalized Medicine","article-title":"Validation of candidate protein\u00a0biomarkers","author":"Pavlou","year":"2013"},{"key":"10.1016\/j.jtho.2018.06.011_bib32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.06.011_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib34","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib36","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin\u00a0as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis Markers"},{"key":"10.1016\/j.jtho.2018.06.011_bib37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib38","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2018.06.011_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant\u00a0mesothelioma 4-10 years in advance of clinical symptoms","volume":"13","author":"Morre","year":"2016","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.jtho.2018.06.011_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MCP.0000000000000167","article-title":"Comparison of mesothelin\u00a0and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma","volume":"21","author":"Creaney","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic\u00a0and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13665-015-0106-8","article-title":"Discovery of new biomarkers for malignant mesothelioma","volume":"4","author":"Creaney","year":"2015","journal-title":"Curr Pulmonol Rep"},{"key":"10.1016\/j.jtho.2018.06.011_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy\u00a0for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib44","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib45","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib46","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","article-title":"Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib47","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","article-title":"Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"22","author":"Weder","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib48","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial","volume":"1","author":"Flores","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","article-title":"Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results","volume":"57","author":"Rea","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib51","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"Van Schil","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.06.011_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-13-22","article-title":"Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma","volume":"13","author":"Federico","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","article-title":"Trimodality treatment of malignant pleural mesothelioma","volume":"3","author":"Batirel","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2018.06.011_bib54","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.lungcan.2005.03.015","article-title":"Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience","volume":"49","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejcts.2006.01.015","article-title":"Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"29","author":"Opitz","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2018.06.011_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8519","article-title":"Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy","volume":"34","author":"Zauderer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib57","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.06.011_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7528","article-title":"A\u00a0randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): clinical results of a single-center trial","volume":"31","author":"Buikhuisen","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy","volume":"108","author":"Boutin","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.jtho.2018.06.011_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","article-title":"A\u00a0randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib61","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","article-title":"A\u00a0randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O\u2019Rourke","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib62","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0360-3016(82)90379-0","article-title":"Radiation therapy in the management of patients with mesothelioma","volume":"8","author":"Gordon","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.06.011_bib64","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib65","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A\u00a0phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.06.011_bib66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.semtcvs.2014.08.003","article-title":"Novel induction therapies for pleural mesothelioma","volume":"26","author":"Donahoe","year":"2014","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.06.011_bib67","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib68","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(11)70307-2","article-title":"The MARS feasibility trial: conclusions not supported by data","volume":"12","author":"Weder","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib69","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(16)00024-3","article-title":"Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?","volume":"17","author":"Rimner","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib70","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ijrobp.2011.09.027","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.06.011_bib71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A\u00a0feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the \u201cSMART\u201d approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib72","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib73","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.06.011_bib74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.06.011_bib75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib76","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib77","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.06.011_bib78","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2018.06.011_bib79","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A\u00a0randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib80","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-14-304","article-title":"Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity","volume":"14","author":"Cortes-Dericks","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib82","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib83","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature01593","article-title":"A\u00a0role for Wnt signalling in self-renewal of haematopoietic stem cells","volume":"423","author":"Reya","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.06.011_bib85","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature06835","article-title":"Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling","volume":"452","author":"Malanchi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.06.011_bib86","first-page":"4239","article-title":"Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth","volume":"27","author":"Uematsu","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib87","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tcb.2012.04.006","article-title":"The Hippo signaling pathway and stem cell biology","volume":"22","author":"Ramos","year":"2012","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jtho.2018.06.011_bib88","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib89","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-15-0583","article-title":"Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in\u00a0vivo by affecting stroma","volume":"15","author":"Meerang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.06.011_bib90","doi-asserted-by":"crossref","first-page":"e57346","DOI":"10.1371\/journal.pone.0057346","article-title":"Gli as a novel therapeutic target in malignant pleural mesothelioma","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.06.011_bib91","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib92","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib93","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib94","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib95","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib96","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"OA13.01 A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib97","doi-asserted-by":"crossref","first-page":"85033","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib98","doi-asserted-by":"crossref","first-page":"e1011492","DOI":"10.1080\/2162402X.2015.1011492","article-title":"Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen","volume":"4","author":"Creaney","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.06.011_bib99","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib100","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 10","key":"10.1016\/j.jtho.2018.06.011_bib101","first-page":"107","article-title":"Oxygen radicals and asbestos-mediated disease","volume":"102","author":"Quinlan","year":"1994","journal-title":"Environ\u00a0Health Perspect"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2018.06.011_bib102","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1289\/ehp.97105s51257","article-title":"Pleural macrophage recruitment and activation in asbestos-induced pleural injury","volume":"105","author":"Choe","year":"1997","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2018.06.011_bib103","first-page":"5922","article-title":"Role of oxyradicals in mutagenicity and DNA damage induced by crocidolite asbestos in mammalian cells","volume":"59","author":"Xu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib104","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1289\/ehp.021101003","article-title":"Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species","volume":"110","author":"Xu","year":"2002","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2018.06.011_bib105","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib106","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00408-015-9744-4","article-title":"Inflammatory cytokines contribute to asbestos-induced injury of mesothelial cells","volume":"193","author":"Acencio","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.jtho.2018.06.011_bib107","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.06.011_bib108","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.06.011_bib109","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1073\/pnas.0803933105","article-title":"The Nalp3 inflammasome is essential for the development of silicosis","volume":"105","author":"Cassel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.06.011_bib110","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jtho.2018.06.011_bib111","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib112","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib113","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2018.06.011_bib114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study","volume":"321","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/carcin\/bgv174","article-title":"Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice","volume":"37","author":"Pietrofesa","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2018.06.011_bib116","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ijc.11710","article-title":"Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention","volume":"109","author":"Catalano","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib117","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-ifnalpha combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib118","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/1078-0432.CCR-11-1808","article-title":"Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation","volume":"18","author":"Burt","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib119","first-page":"55","article-title":"The role of interleukin-6 in malignant mesothelioma","volume":"4","author":"Abdul Rahim","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib121","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1165\/rcmb.2010-0026RT","article-title":"Gene therapy for mesothelioma and lung cancer","volume":"42","author":"Vachani","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtho.2018.06.011_bib122","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib123","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A\u00a0trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib124","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A\u00a0phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib125","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A\u00a0phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtho.2018.06.011_bib126","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.06.011_bib127","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib128","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtho.2018.06.011_bib129","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1200\/JCO.2016.71.2109","article-title":"differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at ClinicalTrials.gov","volume":"35","author":"Tan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.06.011_bib130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.18632\/genesandcancer.124","article-title":"Switching off malignant mesothelioma: exploiting the hypoxic microenvironment","volume":"7","author":"Nabavi","year":"2016","journal-title":"Genes Cancer"},{"key":"10.1016\/j.jtho.2018.06.011_bib131","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7229","article-title":"Targeting hypoxic response for cancer therapy","volume":"7","author":"Paolicchi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.06.011_bib132","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa1709684","article-title":"Nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418307202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418307202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T06:06:06Z","timestamp":1604815566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418307202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":132,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1556086418307202"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.06.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733575977.793551913","asserted-by":"object"}]},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scientific Advances and New Frontiers in Mesothelioma Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}